Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan® | MicrobiomeTrials← Back to trialsNCT06298409
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-02-15Est. Completion: 2026-02-28
Enrollment target: 34 participants Locations- Silicon Valley Gastroenterology, Mountain View, California, United States
Other microbiome trials you might be interested in
Colon Cancer
The goal of this clinical research study is to learn about gastrointestinal symptoms in participants who have undergone …
Houston, United StatesEst. completion Dec 30, 2026
Functional DyspepsiaSmall Intestinal Bacterial Overgrowth
The purpose of this study is to investigate the prevalence of small intestinal bacterial overgrowth (SIBO) in patients w…
Indianapolis, United StatesCompleted Dec 2026
Eosinophilic EsophagitisGastroesophageal Reflux Disease (GERD)GastroparesisFunctional VomitingIrritable Bowel Syndrome (IBS)ConstipationChronic Intestinal Pseudo-obstructionFecal IncontinenceSmall Intestinal Bacterial Overgrowth
Develop a registry (list of patients) with accurate clinical motility diagnosis. This registry will help the doctors to …
Indianapolis, United StatesEst. completion Nov 2026